Pharmaceutical salts of ethionamide with GRAS counter ion donors to enhance the solubility
| dc.contributor.author | Nechipadappu, S.K. | |
| dc.contributor.author | Trivedi, D.R. | |
| dc.date.accessioned | 2026-02-05T09:32:47Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | Pharmaceutical salts of BCS class II second line anti-tuberculosis drug ethionamide (ETH) with various counter ions namely, 2-chloro-4-nitrobenzoic acid (CNB), 2,6-dihydroxybenzoic acid (2,6HBA), 2,3-dihydroxybenzoic acid (2,3HBA) and 2,4-dinitrobenzoic acid (DNB) were synthesized by crystal engineering approach. All the synthesized salts were characterized by various spectroscopic (NMR, FT-IR,), thermal (DSC & TGA) and PXRD techniques. The crystal structure of the synthesized salts was determined by single-crystal X-ray diffraction techniques. All the reported salts, except ETH-2,3HBA exhibited charge assisted acid pyridine heterosynthon. In ETH-2,3HBA hydoxyl pyridine heterosynthon is observed. In ETH-CNB salt, both ionic and neutral acid pyridine heterosynthon were observed in the asymmetric unit. ETH-DNB salt consists of both partial and complete proton transfer from DNB to ETH in the asymmetric unit. All the synthesized salts were found to be non-hygroscopic at accelerated humid condition (~ 75% RH). Solubility experiment has been performed in purified water and in 0.1 N HCl (pH = 1) solution and found that the solubility of ETH-CNB salt was about eight-fold higher soluble than ETH in purified water. The solubility of synthesized salts follows the order of ETH < ETH-2,3HBA < ETH-2,6HBA < ETH-CNB in purified water. © 2016 Elsevier B.V. | |
| dc.identifier.citation | European Journal of Pharmaceutical Sciences, 2017, 96, , pp. 578-589 | |
| dc.identifier.issn | 9280987 | |
| dc.identifier.uri | https://doi.org/10.1016/j.ejps.2016.10.035 | |
| dc.identifier.uri | https://idr.nitk.ac.in/handle/123456789/25831 | |
| dc.publisher | Elsevier B.V. | |
| dc.subject | 2,3 dihydroxybenzoic acid | |
| dc.subject | 2,4 dinitrobenzoic acid | |
| dc.subject | 4 nitrobenzoic acid | |
| dc.subject | counterion | |
| dc.subject | ethionamide | |
| dc.subject | gamma resorcylic acid | |
| dc.subject | unclassified drug | |
| dc.subject | inorganic salt | |
| dc.subject | ion | |
| dc.subject | tuberculostatic agent | |
| dc.subject | Article | |
| dc.subject | controlled study | |
| dc.subject | crystal structure | |
| dc.subject | crystallization | |
| dc.subject | differential scanning calorimetry | |
| dc.subject | donor | |
| dc.subject | drug solubility | |
| dc.subject | hydrogen bond | |
| dc.subject | infrared spectroscopy | |
| dc.subject | molecule | |
| dc.subject | priority journal | |
| dc.subject | proton nuclear magnetic resonance | |
| dc.subject | proton transport | |
| dc.subject | solid state | |
| dc.subject | stoichiometry | |
| dc.subject | synthesis | |
| dc.subject | thermogravimetry | |
| dc.subject | wettability | |
| dc.subject | X ray powder diffraction | |
| dc.subject | chemistry | |
| dc.subject | medicinal chemistry | |
| dc.subject | procedures | |
| dc.subject | solubility | |
| dc.subject | X ray diffraction | |
| dc.subject | Antitubercular Agents | |
| dc.subject | Chemistry, Pharmaceutical | |
| dc.subject | Ethionamide | |
| dc.subject | Ions | |
| dc.subject | Salts | |
| dc.subject | Solubility | |
| dc.subject | Spectroscopy, Fourier Transform Infrared | |
| dc.subject | X-Ray Diffraction | |
| dc.title | Pharmaceutical salts of ethionamide with GRAS counter ion donors to enhance the solubility |
